ImmunityBio (IBRX) Non-cash Items (2014 - 2021)

ImmunityBio (IBRX) has 8 years of Non-cash Items data on file, last reported at $16.2 million in Q2 2021.

• Non-cash Items for Q2 2021 came in at $16.2 million, down 46.63% year-over-year; the trailing twelve-month figure through Jun 2021 was $16.2 million (down 46.63% YoY), and the FY2020 annual result was $29.7 million, up 420.95% from the prior year.
• Non-cash Items slipped to $16.2 million in Q2 2021 per IBRX's latest filing, from $54.3 million in the prior quarter.
• Over five years, Non-cash Items peaked at $54.3 million in Q1 2021 and troughed at $353000.0 in Q2 2019.
• A 5-year average of $14.4 million and a median of $9.2 million in 2018 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2018 and 2020: Non-cash Items slumped 95.28% in 2018, then soared 8498.87% in 2020.
• A 5-year view of Non-cash Items shows it stood at $11.9 million in 2017, then tumbled by 95.28% to $563000.0 in 2018, then jumped by 914.21% to $5.7 million in 2019, then soared by 420.95% to $29.7 million in 2020, then sank by 45.54% to $16.2 million in 2021.
• Business Quant data shows IBRX's Non-cash Items at $16.2 million in Q2 2021, $54.3 million in Q1 2021, and $29.7 million in Q4 2020.